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Abstract 
The hypothesis laid out in this thesis states that the early changes seen on an MRI 
imaging in those with early Charcot neuroarthopathy may be due to mitochondrial 
dysfunction. In a Charcot foot, there is movement between bones. In an attempt to 
prevent this movement, the small muscles of the foot contract continuously when the 
foot is weight bearing. This contraction takes energy in the form of ATP. However, 
the reduction of glucose transport into the muscle cells due to insulin resistance / 
insufficiency, leads to reduction in the ATP producing capacity of the mitochondria. 
The ATP depletion affects the cell membrane gradient leading to mitochondrial and 
cellular swelling. These early cellular changes could then be picked up with MRI 






Charcot neuroarthropathy is an uncommon end organ complication of diabetes that, 
when it occurs, can have significant life changing consequences [1]. It is often 
missed in its early stages and by the time it presents to a specialist foot clinic there is 
often bony deformity and destruction, with a subsequent change in foot shape 
resulting in changes in plantar pressures. These can increase the risk of ulceration 
and infection. Ultimately, the risk of limb loss is high [2], and early immobilisation is 
associated with reduced risk of foot fracture and deformity [3-5]. Thus a diagnosis of 
a “Charcot foot” has significant impact on the individual – physically and 
psychologically, as well as on society in general due to the cost of treating the 
condition [6-8].  
 
The classic way a Charcot foot has been diagnosed is a hot, red, swollen, (painless) 
foot in a person with diabetes. To date, the best way to diagnose the condition is to 
suspect the diagnosis, and then do appropriate imaging. If an initial plain radiograph 
did not show any abnormality, then the most sensitive method has been shown to be 
Magnetic Resonance Imaging (MRI) [9,10].  
 
Population based studies have estimated a prevalence of Charcot neuroarthopathy 
at about 0.1-0.5% in people with diabetes, rising to as much as 13% in high risk 
patients [1]. It normally occurs 8-12 years after diagnosis of diabetes, most 
frequently during the fifth or sixth decade of life and is more common in men [1]. 
Other microvascular end organ damage is often present when a Charcot foot is first 
diagnosed [11,12]. 
 
A diagnosis of Charcot foot is frequently missed by referring physicians prior to 
referral to foot specialists. The delay between problems first noticed by the person 
with diabetes to diagnosis can average up to 29 weeks [13], and such delays lead to 
an increased rate of complications [3]. 
 
However, some individuals present early and do not necessarily have any overt bony 
abnormalities on plain imaging – i.e. classified as Eichenholtz stage 0 or 1 [14]. 
However, these individuals often have a degree of oedema of the soft tissue seen on 
MRI of the foot and ankle, including the small muscles of the foot [15]. An example of 
this is seen in Figures 1-3. The significance of this finding is uncertain. 
 
The purpose of this hypothesis paper is to suggest that the soft tissue oedema seen 
in the small muscles of the foot in an early Charcot foot is a consequence of 
mitochondrial dysfunction in those with diabetes as a result of insulin insufficiency 
and/or insulin resistance.  
 
The sequence of events in the hypothesis put forward in this paper is as follows: 
1. In a Charcot foot there is movement between the bones  
2. In an attempt to prevent the bones from moving, the small muscles of the foot 
contract to try and keep the bones in place and this contraction occurs at all 
times when the foot is weight bearing 
3. This contraction takes energy and if there is insulin insufficiency and/or 
resistance then, because insulin is required for glucose uptake in skeletal 
muscle, intracellular glucose concentrations go down. This reduction in 
glucose concentrations leads to low ATP concentrations being produced  
4. This low ATP concentration leads to the energy required for cellular 
processes (including muscle contraction) becoming depleted 
5. As part of this, cell membranes are unable to maintain their integrity and start 
to leak. This leads to changes in intracellular ionisation with subsequent 
protein leak and changes in water content 
6. The breakdown of cell membrane integrity leads to muscle swelling, and is the 
earliest signal picked up on MRI 
7. Immobilisation of the bones to prevent the muscles from having to try and 
keep them still and thus stop contracting 
 
Thus the treatment for an Eichenholtz stage 0 Charcot foot is early intervention with  
a) Immobilisation of the foot to prevent the muscles from having to try and keep the 
bones still, and thus stop contracting 
b) Improve insulinisation to allow for sufficient glucose uptake to supply the 
mitochondria with substrate 
  
1. In a Charcot foot there is movement between the bones 
 
There are two main theories concerning the development of a Charcot foot. Firstly, 
the neuro-traumatic theory describes the damage caused to the distal sensory 
feedback mechanisms of the foot, leading to repeated trauma and destruction of 
bones and joints. Repeated trauma produces pro-inflammatory cytokines (RANKL, 
NF-κβ, and osteoclasts), which lead to local bony resorption [1]. Secondly, the 
neuro-vascular theory describes the disruption in blood supply regulation due to 
neuropathy which again leads to bone resorption [16,17]. 
 
The structure of the human foot is designed to maintain stable bipedal walking and 
the mechanisms by which this is achieved involve complex movement patterns 
between the bones and ligaments. To achieve an efficient gait, fully functioning 
joints, bones and adequate muscle strength is required [18]. The longitudinal arch is 
able to compress and recoil thus storing elastic energy that can be released each 
time the foot has contact with the floor. During the late stance phase stiffening of the 
midfoot restricts the mobility of the midtarsal joints by inverting the subtalar joint. In 
early stance phase the subtalar joint is everted and the midtarsal joints become more 
flexible [19]. In the Charcot foot, osteolysis leads to progressive bone weakening and 
continuous weight bearing. This then initially leads to microfractures, that if continued 
cause the bones to fracture leading to joint deformities [6]. These deformities make 
the process of maintaining foot shape and stability during the gait cycle more 
challenging.  
 
2. In an attempt to prevent the bones from moving, the small muscles of the foot 
contract to try and keep the bones in place and this contraction occurs at all times 
when the foot is weight bearing 
Muscles contract in order to try and prevent joint dislocation [16]. Common muscle 
contractions in the foot include triceps surae (comprising the gastrocnemius and 
soleus muscles that insert into the calcaneum) and tibialis anterior muscle that 
inserts into the medial cuneiform and first metatarsal bones of the foot. If their 
actions were left unopposed would lead to plantar inclination of the calcaneus and 
dorsal dislocation of cuneiform bone respectively [16]. It has previously been 
recognised that hyperglycaemia leads to tendons and ligaments denaturing by non-
enzymatic collagen glycation, leading to tendon shortening [20]. In addition, the 
peripheral neuropathy associated with diabetes is associated with weakness and 
atrophy of the intrinsic muscles of the foot [21]. Combined, these changes can lead 
to deformity of the joints of the foot which in turn can lead to bone dislocation and 
fragmentation and a change in the biomechanical properties of the foot [16]. 
  
3. This contraction takes energy and if there is insulin insufficiency and/or resistance 
then because insulin is required for glucose uptake in skeletal muscle intracellular 
glucose concentrations go down. This reduction in glucose concentrations leads 
to low ATP concentrations being produced  
 
Insulin binds to the skeletal cell insulin receptor which is autophosphorylated and 
allows for the binding and subsequent phosphorylation of the insulin receptor 
substrates 1 and 2 (IRS-1 and IRS-2). IRS binding to the phosphatidylinositol 3-
kinase (PI3K) leads to the activation of a PI3K-dependent pathway. Within the 
pathway protein kinase B promotes the translocation of glucose transporter (GLUT4) 
to the plasma membrane, which in turn serves for glucose uptake into the muscle 
cell via facilitated diffusion [22,23]. 
 
Glucose is essential for muscle contraction. It has been shown to account for up to 
40% of substrate use for oxidative metabolism during exercise [23]. Contracting 
muscle increases the recruitment of capillaries, which help to increase the surface 
area available to deliver glucose into the skeletal myocytes [23]. Insulin regulates the 
cellular supply of energy by activating the diffusion of glucose into myocytes [24]. 
Insulin has also has been shown to increase mitochondrial capacity for oxidative 
phosphorylation by increasing the concentrations of oxidative enzymes by up to 25% 
in skeletal muscle [25].  
 
Once glucose enters the myocytes with the aid of insulin, mitochondria serve as the 
primary site of its metabolism and thus ATP production [25]. Insulin resistance leads 
to impaired insulin mediated glucose transport into the muscle cells [24]. However, 
with under-insulinisation and resultant hyperglycaemia the excess glucose that is 
taken up by the muscle cells is preferentially metabolised by hexokinase, an enzyme 
with a much higher affinity for glucose, and rapidly transforms glucose into glucose-
6-phosphate. When glucose levels rise in diabetes, the hexokinase pathway is 
saturated forcing more glucose down the sorbitol pathway where enzyme aldose 
reductase converts the glucose to fructose via sorbitol using the enzyme sorbitol 
dehydrogenase. However, the conversion of sorbitol to fructose is very slow, leading 
to build up of sorbitol. This reaction used NADPH as a proton donor. However, 
NADPH is also used by glutathione reductase to convert reduced glutathione (GSH) 
to glutathione disulphide (GSSG). GSH is important because it removes hydrogen 
peroxide. The excessive use of NADPH by the sorbitol pathway, results in lower 
levels of GSH and thus higher concentrations of hydrogen peroxide. The hydrogen 
peroxide is produced by normal mitochondrial respiration that produces free oxygen 
radicals that are themselves converted to hydrogen peroxide by superoxide 
dismutase. When levels of hydrogen peroxide build up, the Fenton reaction liberates 
free radical superhydroxide that is damaging to the surrounding tissues (so called 
‘oxidative stress’).  Thus, high glucose concentrations ultimately lead to a reduction 
in superoxide removal. It is these superoxide molecules that have been implicated in 
damaging strands of DNA. This in turn leads to reductions in intracellular NAD, thus 
slowing the rate of conversion of sorbitol to fructose, leading to a greater build-up of 
sorbitol. Sorbitol diffuses very slowly out through cell membranes, thus intracellular 
accumulation ultimately leads to irreversible cell damage and cell death. 
 
Further damaging processes also occur as a result of high intracellular glucose. As 
mentioned, once the glucose is converted to glucose-6-phosphate, most of it is 
metabolised to fructose-6-phosphate. This molecule is metabolised in 2 main ways. 
Firstly, fructose-6-phosphate is converted into glyceraldehyde-3-phosphate. This is 
metabolised into the highly damaging methylglyoxal. This molecule, as well as other 
reactive glucose metabolites, non-enzymatically attaches to other proteins, resulting 
in the accelerated formation of advanced glycation end-products (AGEs) and so, 
cellular dysfunction. In addition, these proteins may extravasate leading to 
progressive microvascular occlusion – leading to an inability to recruit more 
capillaries in times of need. AGEs can affect muscle function in 2 main ways. Firstly, 
protein glycation affects structure and normal biological function. Secondly the 
binding of AGE to cell surface receptors (RAGE) leads to activation of an 
inflammatory intracellular signalling cascade, increasing the oxidative stress.    
 
The second pathway for fructose -6-phosphate is as a metabolite for the hexosamine 
pathway. This converts fructose-6-phosphate into uridine diphosphate-N-
acetylhexosamine (UDP-GlcNAc). This molecule has an affinity for serine and 
threonine residues on proteins such as Sp1. The binding of UDP-GlcNAc to these 
proteins in turn adversely affects their structure and function and has been 
suggested as a contributory factor to the inflammation and endothelial injury seen in 
hyperglycaemia.  
 
The intracellular hyperglycaemia and activation of the aldose reductase pathway 
described above is also associated with activation of intracellular signalling pathways 
mediated by the mitogen-activated protein (MAP) kinases. These kinases are also 
activated by high levels of oxidised low density lipoprotein (LDL) and RAGE. These 
molecules perform key roles in the intracellular signalling pathways, with at least two 
(p38 and JNK) being activated in the face of intracellular hyperglycaemia. Activation 
is associated with phosphorylation of a variety of proteins, including ion channels, 
disrupting their function, and eventually causing measurable changes in cell 
damage. 
 
The resistance mechanisms could include defects in phosphorylation of the insulin 
receptors or abnormalities in the GLUT4 function [24]. Mitochondrial dysfunction is 
observed in high energy requiring tissues such as muscle tissue [26]. Patients with 
type 2 diabetes have smaller, dysfunctional mitochondrial [27] and do not increase 
their muscle mitochondrial ATP production in the presence of insulin [25]. It has been 
shown that mitochondrial dysfunction is a marker of impaired response to insulin in 
people with diabetes [28,29]. Studies involving people with type 1 diabetes show that 
degradation proteins of mitochondrial function are upregulated [30]. In addition to the 
abnormal metabolic pathways described above, in people with type 1 diabetes 
reduced insulin action in insulin resistant states causes muscle mitochondrial 
dysfunction, with multiple defects in mitochondrial gene transcript concentrations 
leading to reduced maximal ATP production [31,32]. Structurally, muscles of people 
with diabetes appear fragmented when compared to healthy subjects that have a 
large network of fused mitochondria [26]. Type I muscle fibres, which have high 
oxidative enzyme capacities, have more GLUT-4 transporters than type II muscle 
fibres. Insulin resistant muscles however have lower percentages of type I muscle 
fibres and lower GLUT-4 protein within their muscle fibres [25]. 
 
The contractile properties of skeletal muscle rely on muscle mitochondria which 
constantly adapt to meet new demands [19]. To maintain healthy mitochondria, there 
must be a balance between mitochondrial biogenesis and mitophagy, but also 
between ATP and reactive oxygen species production [33]. Alterations to the energy 
supply of the mitochondria affect the balance between biogenesis and mitophagy 
[30]. Mitochondrial oxidative function is controlled by mammalian target of rapamycin 
(mTOR) [34]. mTOR balances energy metabolism by affecting mitochondrial 
transcriptor regulation via PPARɣ coactivator 1α, which in turn regulates 
mitochondrial biogenesis [30]. Insulin regulates mTOR activity [30], highlighting its 
importance in the ATP-dependent processes of the body. Protective measures 
involve upregulation of signals to initiate mitophagy and ensure that damaged 
mitochondria are removed from the tissue [30]. For example, insulin deprivation 
leading to reactive oxygen species formation within the cell stimulates the activation 
of Parkinson protein 7 (PARK7/DJ-1) which in turn regulates mitophagy [35].  
 
During metabolic stress induced by endurance exercise mitochondrial biogenesis 
can be increased. However in chronic disease, such as diabetes, it has been shown 
to be decreased [19]. The inflammation associated with decreased mitochondrial 
numbers associates with a reduction of oxidative phosphorylation, leading to further 
reduced cellular metabolism and impaired muscle function [36,37].  
  
4. This low ATP concentration leads to the energy required for cellular processes 
(including muscle contraction) becoming depleted 
 
ATP production requires oxidation of NADH or FADH2 and oxidative phosphorylation 
of ADP to ATP. NADH and FADH2 are generated during Krebs cycle of glucose, 
glycolysis and beta oxidation of fatty acids [38]. Electrons from NADH and FADH2 
are transferred to respiratory chain complexes and the final product is water. Protons 
produced during oxidation are pumped into the inter-mitochondrial membranes 
through respiratory complexes I, III, and IV, thus producing an electrochemical 
gradient [38]. The gradient drives ATP synthase to produce ATP from ADP [38]. 
There is constant utilisation within the cells and in intense or prolonged exercise the 
ATP concentrations are reduced [23]. NADH oxidase of the mitochondrial electron 
transport chain within the muscle is reduced in subjects with type 2 diabetes [39]. 
Therefore in both resting and energy requiring states, it may be a reasonable to 
assume that the ATP producing capacity of people with diabetes would be affected.  
 
ATP production maintenance within the muscle is so important, that myofibres 
contain two types of mitochondrial populations, the subsarcolemmal mitochondria 
and intermyofibrillar mitochondria [40]. These are interconnected and rapidly 
distribute energy through myofibres in order to provide sufficient amounts of energy 
to keep up with rapidly changing requirements [40]. 
 
In a study comparing skeletal muscle mitochondrial physiology between insulin 
deprived streptozotocin (STZ) mice and non-diabetic controls, the level of 
mitochondrial complexes I, II, and V were reduced in the STZ treated mice [35]. The 
effects of insulin deprivation lead to reduction in mitochondrial proteins, including the 
mitochondrial complexes and adenine nucleotide translocases. Adding to this, 
translocation elongation factor involved in the regulation of mitochondrial protein 
synthesis was downregulated. Higher mitochondrial leak and lower phosphorylation 
efficiency was noted, along with overall mitochondrial ATP synthesis reduction [35]. 
These effects were reversed by insulin replacement [35].  
 
These authors also found that uncoupled respiration led to higher reactive oxygen 
species production, which in turn would lead to DNA damage and protein 
degradation. These findings are supported by another study that found that ADP-
stimulated respiration with pyruvate and malate in vastus lateralis muscles in people 
with type 2 diabetes was reduced and highlighted the reduction of functional capacity 
in those patients [41].  
 
Insulin regulates mixed muscle protein synthesis, however in diabetes and in aging 
the function and synthesis of mitochondrial protein is reduced [42]. High insulin 
concentrations have been shown to stimulate mitochondrial protein synthesis within 
the muscle when infused with essential amino acids [42]. On a cellular level, insulin 
replacement in STZ mice restored mitochondrial protein concentrations and reduced 
reactive oxygen species production to concentrations close to the non-diabetic group 
- but not fully [35]. 
 
In patients with type 1 diabetes the insulin deficiency leads to a reduction in ATP 
production in the muscles, but treatment with insulin allows for the maintenance of 
mitochondrial function within muscles [30]. Insulin infusions have been shown to 
increase mitochondrial capacity for oxidative phosphorylation within skeletal muscle 
[25]. Previous work has shown that short term hyperinsulinaemia stimulated 
myocellular ATP production in healthy subjects but not in those with type 1 diabetes 
mellitus, who had 42% lower intramyocellular glucose-6-phosphate levels suggesting 
an impairment of glucose disposal [43]. Mitochondrial ATP production did not change 
in the muscles of those with type 2 diabetes mellitus [25]. Mitochondrial oxidative 
enzymes citrate synthase activity and COX activity increased with insulin infusions 
within the skeletal muscle. The functional synthesis rate of mitochondrial proteins 
also increases which may in turn lead to increased ATP producing units [25].  
  
5. As part of this, cell membranes are unable to maintain their integrity and start to 
leak. This leads to changes in intracellular ionisation with subsequent protein leak 
and changes in water content 
 
It is evident that proteins play a key role in maintaining the integrity of the cell 
membrane [44]. Lack of insulin increases the breakdown of proteins and this effect is 
more prominent within skeletal muscle [42]. Highly reactive oxygen species 
produced within muscle cells during low energy states lead to protein degradation 
and cause DNA damage [35]. When ATP concentrations decrease dramatically 
during states of insulin deficiency, it results in apoptosis [45]. The cells lose their 
ability to maintain intracellular homeostasis of ions and water, which can lead to 
rupture of the plasma membrane and leakage of the cytoplasm into the extracellular 
environment [45]. The level of ATP depletion triggering apoptosis has been studied, 
and depletion of ATP concentration of over 50% was found to be the trigger [46]. 
 
A key factor in maintaining cellular integrity is the regulation of ion gradients against 
cell membranes. The ion pumps responsible are ATPases (Ca2+ ATPase, Na+/K+ 
ATPase, mitochondrial H+ (F1) ATPase, H+/K+ ATPase) which utilise ATP to 
maintain ion balance across the cell membrane [47]. When oxidative phosphorylation 
fails and intracellular glucose concentrations are depleted, cells become deplete of 
ATP [46]. Ion pumps and other metabolic processes use up the remaining ATP, and 
then the Na+/K+ pump activity starts to become affected leading to disruption of the 
ratio of ions across the cell membrane [46]. Any compromise in the cell membrane 
functioning can have a detrimental effect on the cell [48]. Disruptions in the plasma 
membranes are particularly high in skeletal muscle due to continuous contraction 
and lengthening occurring in physiological states [48]. These disruptions are 
resealed by utilisation of extracellular calcium ions and thus prevent triggering of cell 
death in large numbers [48]. Specifically the cell utilises calcium triggered exocytosis 
to deliver excess membrane to form a membrane patch at the site of injury [48]. 
However during ATP depletion, calcium homeostasis can also be disrupted [46], 
therefore could affect the ability of the cells to repair damaged cell membranes.  
 
Various proteins have been implicated in the formation of the patch to prevent the 
disruption of the cell membrane [44]. Annexins are a large protein family that bind 
phospholipids in a calcium dependent manner and regulate endocytosis and 
exocytosis that lead to stabilisation of the membrane compartments [44]. Annexin A6 
has been shown to accumulate the fastest at the injury site (within 20 seconds) [44]. 
Combined with dysferlin they act to formulate a repair patch, at the damaged cell 
membrane sites and increase membrane resealing [44]. 
 
Energy depletion has also been implicated in the breakdown of the cell membrane 
lipids [46]. In early studies of renal epithelial cells, it was found that depletion of ATP 
within the cells was much faster when glucose was absent. When examining the cell 
morphology of cell cultures depleted of glucose, it was found that no cells had 
normal morphology [46]. Instead cell swelling, mitochondrial swelling and disrupted 
cell membrane were observed [46].  
 
Another important communication system exists between mitochondria and the 
endoplasmic reticulum. This takes place via mitochondrial associated endoplasmic 
reticulum membranes (MAMs) [49]. The structure of MAMs is supported by FUNDC1 
proteins within the mitochondria [49]. It has been found that MAM concentrations and 
FUNDC1 expression are elevated in cardiac myocytes of diabetic mice [49]. An 
important observation is that MAM overexpression causes aberrant calcium 
signalling and in turn leads to mitochondrial dysfunction. When glucose 
concentrations are lower to establish normoglycaemia, MAM levels are reduced and 
calcium concentrations return to baseline within 8 hours [49]. This highlights the 
importance of establishing good glycaemic control to try and enable resolution of 
mitochondrial dysfunction in people with diabetes. 
 
Endurance exercise training leads to increases of mitochondrial volume of up to 50% 
in training interventions of a few weeks in previously untrained subjects [50]. Bedrest 
and microgravity conditions lead to losses of both myofibrillar and mitochondrial 
volume, likely as a consequence of the decrease in metabolic and mechanical stress 
on muscle tissue. Permanent severe hypoxia leads to a loss of muscle mass and 
muscle oxidative capacity; however, hypoxia signalling events are triggered, which 
lead to distinct reprogramming phenomena of the transcriptome of the muscle cells. 
  
6. The breakdown of cell membrane integrity leads to muscle swelling, and is the 
earliest signal picked up on MRI 
 
Initial assessment of Charcot neuroarthropathy is undertaken within plain 
radiography [51]. There are three stages of the neuroarthopathy (I-III) that were 
described by Eichenhotlz, which represent the natural evolution of the condition. 
However in stage 0, which was later added, there is no bony deformity and no 
changes that can be identified on plain radiograph [51]. MRI images are superior in 
detecting early changes [52] and are the most sensitive method to achieve this [51]. 
Muscle oedema can correspond to areas of low to intermediate signal in T1 weighted 
images and high signal in T2 weighted images [52]. 
  
7. Immobilisation of the bones to prevent the muscles from having to try and keep 
them still and thus stop contracting 
 
Early diagnosis and treatment of Charcot stage 0 is crucial in preventing bony 
destruction and deformity [51]. Offloading and immobilisation of the affected foot at 
stage 0 can help reduce progression to stage 1 [51]. A retrospective cohort study 
evaluating acute Charcot foot treatment in 71 patients, demonstrated that diagnosis 
and treatment of Charcot foot at stage 0 is more efficient [53]. The treatment 
instigated was complete immobilisation and offloading with subsequent total contact 
cast. Even though the time to heal was not significantly shorter between patients with 
stage 0 and stage 1 disease, the rate of healing was different [53]. 70% of patients 
with stage 0 disease healed without deformity, whilst only 32% of patients with stage 
1 disease healed without deformity [53]. This highlights the importance of diagnosing 





The hypothesis laid out in this thesis states that the early changes seen on an MRI 
scan in those with early Charcot maybe due to mitochondrial dysfunction. The 
reduction of glucose transport into the muscle cells due to insufficiency of insulin, 
leads to reduction in the ATP producing capacity of the mitochondria. With 
dysfunctional mitochondria being present in people with diabetes, these effects of 
energy depletion would be expected to be exacerbated. The ATP depletion affects 
the cell membrane gradient leading to mitochondrial and cellular swelling. These 
early cellular changes could then be picked up with MRI imaging as muscle oedema.  
What remains unknown however, is do these changes occur in those who develop 
Charcot who do not have diabetes. Thus further work is needed – such as skeletal 
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Legend to Figures 
 
Figure 1 
AP plain radiograph of the weight bearing right foot showing no obvious bony 
abnormality (The same patient is seen in all three figures and the images were all 
done in the same week) 
 
Figure 2 
Lateral plain radiograph of the weight bearing right foot showing no obvious bony 
abnormality (The same patient is seen in all three figures and the images were all 
done in the same week) 
 
Figure 3 
Magnetic Resonance Image showing no bony abnormality. There is oedema seen 
within the soft tissues of the dorsal aspect of the foot as well as the muscles of the 
sole of the foot. (The same patient is seen in all three figures and the images were 
all done in the same week) 
